Med-Tech Innovation January 19, 2024

Quibim, a company using imaging biomarkers for precision medicine, has added a new cancer detection capability to its prostate tool based on AI, QP-Prostate. The updated product, which uses algorithms trained on actual pathology data as ground truth, has been given a CE mark for the European Union and a UKCA mark for the United Kingdom.

As MRI scans have become standard-of-care for prostate cancer, and populations at higher risk of the disease continue to grow, many radiology departments have not had the proper resources in place to handle the avalanche of advanced medical imagery needing to be analysed to appropriately manage prostate cancer patients. QP-prostate, one of Quibim’s flagship products, was developed to overcome this challenge by using AI...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Pharma / Biotech, Precision Medicine, Technology
Phenomix Sciences Raises $7.8M to Acclerate Obesity Precision Medicine Adoption
Sylvester Cancer Center Launches Precision-Medicine Focused Brain Tumor Institute
Largest GWAS for Breast Cancer in Women of African Ancestry Reveals Key Variants
New Study Links Ribosomal DNA Copy Number with Disease Risk
Navigating the Complexities of Payment for Genetic Testing

Share This Article